factor VII

(redirected from Factor VIIa)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to Factor VIIa: factor VIII, Novoseven
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.factor VII - a coagulation factor formed in the kidney under the influence of vitamin K
clotting factor, coagulation factor - any of the factors in the blood whose actions are essential for blood coagulation
References in periodicals archive ?
Catalyst had previously entered into a manufacturing agreement with CMC Biologics for its next-generation Factor VIIa product marzeptacog alfa in May 2016, making this the second manufacturing agreement Catalyst has with the company.
Contract award notice: Concentrate of recombinant coagulation factor viia.
Since joining the company in September 2015, Hetherington has successfully led the Pfizer-to-Catalyst technology transfer of its next-generation Factor VIIa clinical candidate and has been instrumental in advancing its next generation Factor IX clinical manufacture and associated program activities.
Patent and Trademark Office for long lasting recombinant heparosan Factor VIIa conjugate.
KEY WORDS: Recombinant factor VIIa, gastrointestinal bleeding, hematopoietic stem cell transplantation, thrombocytopenia, hemostatic treatments.
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
Together with approximately USD 35m net cash on Targacept's balance sheet, the combined company has approximately USD 39m in cash to advance its research and development efforts, including the clinical development of CB 813d, Catalyst's next-generation and long-acting coagulation Factor VIIa.
The facility would house genetically engineered rabbits raised to produce milk loaded with Factor VIIa, a blood-clotting agent for patients with hemophilia.
2-6) In life-threatening bleeding situations, even without pre-existing coagulopathies, recombinant factor VIIa (rFVIIa) seems to be a possible choice for treatment.
It also is developing versions of Factor VIIa and Factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide for diabetes and obesity.
Examples of new drugs that are covered include levosimendan, sugammadex, oseltamivir, dexmedetomidine, pregabalin and recombinant Factor VIIa.